Literature DB >> 19631573

Reversal effect of Raf-1/Mdr-1 siRNAs co-transfection on multidrug resistance in KBv200 cell line.

Yan Dong1, Shujuan Shao, Jun Hu, Peiman Yang.   

Abstract

Multidrug resistance (MDR) is a major barrier for chemotherapy of many cancers. Mdr-1 plays a key role in the development of MDR as extensively verified. However, the role of Raf-1 overexpression in the development of multidrug resistance in human squamous carcinoma (KBv200) cells remains largely unknown. The aim of this study was to investigate the correlation of Raf-1 overexpression with the development of multidrug resistance in KBv200 cells. Furthermore, we explored the reversal effect of Raf-1 siRNA transfection and Raf-1/Mdr-1 siRNAs co-transfection on the multidrug resistance of KBv200 cells and potential mechanism of reversing the multidrug resistance. MTT and flow cytometry assay were used to investigate the reversal effect of single transfection with either Raf-1 or Mdr-1 siRNA and double transfection with Raf-1/Mdr-1 siRNAs to vincristine of KBv200 cells. RT-PCR, immunofluorescence and Western Blot were used to detect mRNA and protein expression of Raf-1 and multidrug-resistant gene Mdr-1. The results of gene detection showed that the expression levels of both Raf-1 and Mdr-1 were greatly decreased upon Raf-1 silencing alone or in combination with Mdr-1 silencing. Raf-1 or Mdr-1 siRNA single transfection could reverse the multidrug resistance of KBv200 cells effectively. Compared with single transfection, Raf-1/Mdr-1 siRNAs co-transfection can significantly reduce IC(50) values and increase the apoptotic rates of KBv200 cells. The above results suggested that Raf-1 gene may be a novel target for reversing the multidrug resistance of human squamous carcinoma cells. Raf-1/Mdr-1 siRNAs co-transfection might be a promising approach to abrogate the multidrug resistance of cancer cells. The potential mechanism may be via inhibiting the multidrug-resistant gene Mdr-1 expression efficiently.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19631573     DOI: 10.1016/j.oraloncology.2009.05.642

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  3 in total

1.  Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells.

Authors:  Ki-Hwan Eum; Soon Kil Ahn; Hara Kang; Michael Lee
Journal:  Mol Cell Biochem       Date:  2012-09-02       Impact factor: 3.396

2.  Emodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro.

Authors:  Dian-Lei Liu; Heqi Bu; Hong Li; Hui Chen; Hong-Chun Guo; Zhao-Hong Wang; Hong-Fei Tong; Zhong-Lin Ni; Hai-Bin Liu; Sheng-Zhang Lin
Journal:  Int J Oncol       Date:  2011-12-07       Impact factor: 5.650

3.  Establishment of a new OSCC cell line derived from OLK and identification of malignant transformation-related proteins by differential proteomics approach.

Authors:  Yan Dong; Qun Zhao; Xiaoyan Ma; Guowu Ma; Caiyun Liu; Zhuwen Chen; Liyuan Yu; Xuefeng Liu; Yanguang Zhang; Shujuan Shao; Jing Xiao; Jia Li; Weimin Zhang; Ming Fu; Lijia Dong; Xiandong Yang; Xu Guo; Liyan Xue; Fei Fang; Qimin Zhan; Lihua Zhang
Journal:  Sci Rep       Date:  2015-08-03       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.